DERM
Price
$5.95
Change
-$0.00 (-0.00%)
Updated
Oct 8 closing price
Capitalization
181.48M
34 days until earnings call
Intraday BUY SELL Signals
RDY
Price
$12.20
Change
-$0.08 (-0.65%)
Updated
Oct 8, 04:59 PM (EDT)
Capitalization
10.63B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DERM vs RDY

DERM vs RDY Comparison Chart in %
View a ticker or compare two or three
VS
DERM vs. RDY commentary
Oct 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a StrongBuy and RDY is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DERM vs RDY: Fundamental Ratings
DERM
RDY
OUTLOOK RATING
1..100
5632
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
17
Undervalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9669
PRICE GROWTH RATING
1..100
6357
P/E GROWTH RATING
1..100
3310
SEASONALITY SCORE
1..100
25n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (17) in the Pharmaceuticals Generic industry is somewhat better than the same rating for DERM (58) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than DERM’s over the last 12 months.

RDY's Profit vs Risk Rating (93) in the Pharmaceuticals Generic industry is in the same range as DERM (100) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

RDY's SMR Rating (69) in the Pharmaceuticals Generic industry is in the same range as DERM (96) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

RDY's Price Growth Rating (57) in the Pharmaceuticals Generic industry is in the same range as DERM (63) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

RDY's P/E Growth Rating (10) in the Pharmaceuticals Generic industry is in the same range as DERM (33) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DERMRDY
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
52%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
57%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
53%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
44%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 3 days ago
48%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
55%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
47%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
56%
COMPARISON
Comparison
Oct 09, 2026
Stock price -- (DERM: $5.95 vs. RDY: $12.20)
Brand notoriety: DERM: Notable vs. RDY: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DERM: 108% vs. RDY: 85%
Market capitalization -- DERM: $181.48M vs. RDY: $10.63B
DERM [@Pharmaceuticals: Generic] is valued at $181.48M. RDY’s [@Pharmaceuticals: Generic] market capitalization is $10.63B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 1 FA rating(s) are green while RDY’s FA Score has 2 green FA rating(s).

  • DERM’s FA Score: 1 green, 4 red.
  • RDY’s FA Score: 2 green, 3 red.
According to our system of comparison, RDY is a better buy in the long-term than DERM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 6 bullish TA indicator(s).

  • DERM’s TA Score: 5 bullish, 6 bearish.
  • RDY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RDY is a better buy in the short-term than DERM.

Price Growth

DERM (@Pharmaceuticals: Generic) experienced а -11.46% price change this week, while RDY (@Pharmaceuticals: Generic) price change was -0.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.77%. For the same industry, the average monthly price growth was -4.84%, and the average quarterly price growth was +24.37%.

Reported Earning Dates

DERM is expected to report earnings on Nov 11, 2026.

RDY is expected to report earnings on Oct 23, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
DERM
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DBO24.130.59
+2.51%
Invesco DB Oil Fund (DBO)
SAGP35.260.24
+0.67%
Strategas Global Policy Opportunities ETF (SAGP)
VTV219.631.42
+0.65%
Vanguard Morningstar Value ETF (VTV)
DJP52.210.28
+0.54%
iPath Bloomberg Commodity Index Total Return ETN (DJP)
GOU25.62-0.42
-1.61%
GraniteShares 2x Long GOOGL Daily ETF (GOU)

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and VTRS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and VTRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
-0.57%
VTRS - RDY
28%
Poorly correlated
-0.29%
HROW - RDY
26%
Poorly correlated
-0.33%
DERM - RDY
25%
Poorly correlated
N/A
LFCR - RDY
24%
Poorly correlated
-0.16%
SNDL - RDY
24%
Poorly correlated
-2.40%
More